| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | — | — | — | — | — | — |
| 3d | — | — | — | — | — | — |
| 1w | — | — | — | — | — | — |
| 1m | — | — | — | — | — | — |
| 3m | — | — | — | — | — | — |
| 6m | — | — | — | — | — | — |
| 1y | — | — | — | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
Novo Nordisk's Wegovy pill has FDA approval and demonstrates superior efficacy (16.6% weight loss) compared to Eli Lilly's orforglipron (12.4%), with competitive pricing at $149. This gives NVO a significant commercial and competitive advantage in the obesity drug market.
Microsoft is a diversified company with strong competitive moats in OS and enterprise software, plus rapid Azure growth at 38%. The author sees this as a rare buying opportunity similar to valuations available 6 years ago.
Novo Nordisk is poised for long-term growth driven by a structural shift of European pension funds toward European equities, combined with rising diabetes prevalence and sustained demand for weight-loss treatments. Despite near-term headwinds from competition and regulatory risk, these tailwinds should outweigh them over a 3-year horizon.
End of results.